PARP1 and urothelial carcinoma: We show here that the combination therapy of the CDK4/6 inhibitor Palbociclib and the PARP inhibitor Talazoparib has synergistic anticancer effects on RB-positive urothelial carcinoma cells in vitro and in xenograft models.